PharmaVoice’s Crystal Ball: What’s next for AI and drug R&D
As AI finds solid footing in pharma R&D, the technology is slated to yield significant rewards. Industry leaders expect that up to 30% of preclinical work could soon be accomplished using some form of AI, according to a recent survey, and ultimately predict a 16% reduction in drug development costs with the use of AI in […]
Trendspotting: Embracing AI, DEI Changes, Restrategizing Research Sites
To kick off 2026, we spoke with industry experts and leaders in the Clinical Research News community about what they expect and look forward to in the new year. More than ever before, artificial intelligence took center stage.
CluePoints: how proactive oversight and AI are reshaping clinical trial data management
Dan Beaudry, market owner for risk-based quality management (RBQM) at CluePoints, explains how regulatory shifts and AI-driven tools are transforming clinical trial data oversight. With ICH E6(R3) introducing risk-based approaches and the FDA signaling growing acceptance of algorithmic support, sponsors and CROs are operationalizing RBQM with adaptive site monitoring, automation, and predictive analytics. According to […]
Six geese a-laying: CluePoints’ AI predictions for 2026
Returning to the series is CluePoints, with Sophie Henderson, senior strategic consultant, sharing her hopes and expectations for how AI, analytics and risk-based approaches will continue to shape clinical development. From agentic AI to trust, transparency and smarter decision making, these predictions explore how the industry can turn technological potential into real-world impact in the […]
Predictions for the Future of Risk-Based Quality Management (RBQM)
Regulatory changes, including the launch of ICH E6(R3) and Good Clinical Practice (GCP) updates, have highlighted the value of, and need for, risk-based quality management (RBQM) approaches. With benefits including higher quality in clinical trial implementation and lower monitoring costs, the average proportion of clinical trial implementing RBQM is expected to increase to around 80% […]
Today Discover Pharma launches its annual 12 Days of Christmas campaign featuring CluePoints insight on RBQM
Sophie Henderson, Senior Strategic Consultant at CluePoints, said: “This year we have seen risk-based quality management (RBQM) take center stage in clinical research. ICH E6(R3) emphasized the importance of flexibility, critical thinking and quality-by-design. With regulatory backing and increasing adoption, the industry is learning more about how RBQM can unlock value for drug development and […]
The Modern CRA: Operationalizing Data-Driven Site Success
As clinical trials become more complex, leading sponsors are shifting the focus of their clinical research associates (CRAs) from traditional compliance monitoring to proactive, data-enabled site support and oversight. Skill development, structural changes, and the use of advanced analytics are modernizing the CRA role—and the way we monitor clinical trial sites.
KRI Overload: When More Isn’t Better
Using AI and Advanced Analytics to Transform Clinical Trials
Ken McFarlane of CluePoints shares insight on better, smarter ways to detect risk, streamline data review, and automate oversight.
Reactions to Being “Powered By Purpose” on Clinical Trials Day 2025
As a follow-up to Clinical Trials Day 2025, held on May 20 with the theme of being “Powered By Purpose,” a collection of industry thought leaders shared their perspectives with ACRP on their clinical research powers, and on what they see as being the greatest current challenges and opportunities for the enterprise.
